Ipravent
Anticholinergic Bronchodilator Inhaler for COPD and Chronic Asthma
Quick Facts About Ipravent
Key Takeaways About Ipravent
- Maintenance bronchodilator: Ipravent is used as regular maintenance therapy for COPD and chronic asthma – it is not a rescue inhaler for sudden breathlessness
- Anticholinergic mechanism: Works by blocking muscarinic receptors in the airways, causing bronchial smooth muscle to relax and allowing easier airflow
- Keep away from eyes: Accidental eye contact can cause pain, dilated pupils, blurred vision, and may trigger narrow-angle glaucoma requiring immediate treatment
- Dry mouth risk: Long-term use may cause persistent dry mouth that can lead to dental damage – brush with fluoride toothpaste twice daily
- Adults only: This pressurised inhaler formulation is approved for adults only, including elderly patients – it is not suitable for children or adolescents
What Is Ipravent and What Is It Used For?
Ipravent is a pressurised metered-dose inhaler containing ipratropium bromide, an anticholinergic bronchodilator. It is prescribed for adults with chronic obstructive pulmonary disease (COPD) or chronic asthma to make breathing easier by relaxing and opening the airways.
Ipravent belongs to the group of medicines known as anticholinergic (or antimuscarinic) bronchodilators. The active ingredient, ipratropium bromide, works by blocking the action of acetylcholine at muscarinic M3 receptors in the smooth muscle lining the bronchial tubes. When acetylcholine binds to these receptors, it causes the airway muscles to contract and narrow, increasing resistance to airflow. By blocking this signal, ipratropium bromide allows the bronchial smooth muscle to relax and the airways to dilate, reducing airflow resistance and making breathing easier.
In patients with chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema, the airways become chronically narrowed and inflamed, trapping air in the lungs and making it difficult to exhale. Ipravent helps to open these narrowed airways, improving ventilation and reducing symptoms such as breathlessness, wheezing, and chest tightness. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recognises short-acting anticholinergics like ipratropium as an important component of COPD management, particularly for symptomatic relief and as part of combination bronchodilator therapy.
In patients with chronic asthma, ipratropium bromide provides an additional bronchodilatory effect that complements beta-2 agonist inhalers such as salbutamol. While beta-2 agonists work on a different set of receptors to relax airway muscles, ipratropium targets the cholinergic pathway, meaning the two types of bronchodilators can work together for enhanced airway opening. Ipratropium is particularly useful in patients who do not respond adequately to beta-2 agonists alone or who experience significant side effects from higher doses of beta-agonist therapy.
It is important to understand that Ipravent is a maintenance treatment, not a rescue inhaler. Its onset of action is approximately 15 minutes, with peak effect occurring at 1–2 hours and a duration of action of 4–6 hours. For acute breathlessness or sudden asthma attacks, a fast-acting beta-2 agonist (such as salbutamol) should be used instead. Always carry your rescue inhaler separately and ensure you know which inhaler to use in an emergency.
Ipratropium bromide was first introduced for clinical use in the 1970s and has become one of the most widely used bronchodilators worldwide. It is included on the World Health Organization's List of Essential Medicines, reflecting its established role in respiratory care. Ipravent is one of several branded formulations of ipratropium bromide available internationally, with Atrovent being another well-known brand. Each Ipravent canister contains 200 metered doses.
What Should You Know Before Using Ipravent?
Before starting Ipravent, tell your doctor about all your medical conditions, especially glaucoma, prostate problems, bladder obstruction, or cystic fibrosis. Ipravent is contraindicated if you are allergic to ipratropium bromide or atropine-like substances.
Contraindications
You should not use Ipravent if any of the following apply to you:
- Allergy to ipratropium bromide or any of the other ingredients in the inhaler (listed in the contents section below)
- Allergy to atropine or atropine-like (anticholinergic) medicines – such as hyoscine (scopolamine) or hyoscyamine, as these are chemically related to ipratropium bromide
If you are unsure whether any of these apply to you, talk to your doctor or pharmacist before using Ipravent.
Warnings and Precautions
Talk to your doctor or pharmacist before using Ipravent if you have or are at risk of any of the following conditions:
- Narrow-angle glaucoma (or risk of developing it) – ipratropium can increase intraocular pressure, which may worsen this condition. If the spray gets into your eyes, it can trigger an acute glaucoma attack requiring immediate medical treatment
- Difficulty urinating (urinary retention) – anticholinergic medications can make it harder to empty the bladder
- Prostate problems (prostatic hyperplasia in men) – the anticholinergic effect may worsen urinary symptoms
- Cystic fibrosis – patients with cystic fibrosis may be more prone to gastrointestinal motility disturbances when using anticholinergic agents
- Acute or rapidly worsening breathlessness – Ipravent is not designed for rapid relief of acute bronchospasm. If your breathing suddenly deteriorates, seek immediate medical attention and use your rescue inhaler
- Swelling of the face, tongue, or throat (angioedema)
- Difficulty swallowing
- Hives (urticaria) and breathing difficulties
In rare cases, Ipravent can cause allergic reactions immediately after use. These may manifest as hives or swelling of the upper airways.
Ipravent can cause dry mouth, which during long-term treatment may lead to damage to the teeth and oral mucosa. You should brush your teeth thoroughly with fluoride toothpaste twice daily and maintain regular dental check-ups.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before using Ipravent. As a precautionary measure, the use of Ipravent should be avoided during pregnancy. There is limited clinical experience with ipratropium bromide use during pregnancy, and the potential risks to the developing foetus have not been fully established.
It is not known whether ipratropium bromide passes into breast milk. If you are breastfeeding, consult your doctor before using Ipravent. Your doctor will assess whether the benefit of treatment outweighs any potential risk to your baby.
Driving and Operating Machinery
While using Ipravent, you may experience dizziness, difficulty focusing, visual disturbances, or blurred vision. If you experience any of these symptoms, do not drive or operate machinery until the effects have completely resolved. You are responsible for assessing whether you are fit to drive or perform tasks requiring alertness. Consider all the information in this guide when making this assessment, and discuss any concerns with your doctor.
Ethanol (Alcohol) Content
Ipravent contains 8.4 mg of ethanol (alcohol) per spray dose. The small amount of alcohol in each dose of this medicine is equivalent to less than 4.3 ml of beer or 1.72 ml of wine. This low amount of alcohol does not produce any noticeable effects and is not clinically significant.
How Does Ipravent Interact with Other Drugs?
Ipravent can interact with other inhaled bronchodilators and xanthine-based medicines. Tell your doctor about all medications you are taking, including herbal products. The combination of ipratropium with beta-2 agonists like salbutamol can provide additive bronchodilation.
Although ipratropium bromide acts primarily locally in the lungs with minimal systemic absorption, it is still important to inform your doctor about all medicines you are using. Certain medications can enhance or modify the effects of Ipravent, or Ipravent may alter how other medicines work.
Known Interactions
| Drug / Class | Category | Effect | Recommendation |
|---|---|---|---|
| Salbutamol (albuterol) | Short-acting beta-2 agonist (SABA) | Additive bronchodilatory effect through complementary mechanisms | Commonly combined; monitor for increased heart rate or tremor |
| Theophylline | Xanthine bronchodilator | Additive bronchodilation; both relax airway smooth muscle via different pathways | Monitor theophylline levels and watch for signs of toxicity (nausea, tachycardia) |
| Aminophylline | Xanthine bronchodilator | Similar additive effect as theophylline | Careful monitoring of serum drug levels and clinical response |
| Other anticholinergic agents | Various (e.g. tiotropium, glycopyrronium) | Increased anticholinergic side effects (dry mouth, urinary retention, constipation) | Avoid combining multiple inhaled anticholinergics unless specifically directed by your doctor |
| Long-acting beta-2 agonists (LABAs) | Bronchodilators (e.g. salmeterol, formoterol) | Enhanced bronchodilation through complementary receptor pathways | Frequently used in combination for COPD; follow doctor's instructions |
If you are using other inhaled medications, always use Ipravent as directed by your doctor. In many COPD management plans, ipratropium bromide is deliberately combined with short-acting beta-2 agonists for improved symptom control. The GOLD guidelines recognise this combination as an effective approach for symptomatic relief in COPD, as the two drug classes target different pathways to achieve bronchodilation.
Ipravent can be used with a compatible spacer device such as the Aerochamber Plus. A spacer may be particularly helpful for patients who have difficulty coordinating the timing of pressing the canister and breathing in. Ask your doctor, nurse, or pharmacist for guidance on using a spacer with your inhaler.
What Is the Correct Dosage of Ipravent?
The recommended dose for adults is 1–2 puffs (20–40 micrograms) inhaled four times daily. The maximum daily dose is 12 puffs (240 micrograms). Always use Ipravent exactly as prescribed by your doctor.
Always use Ipravent exactly as your doctor has told you. Do not take more inhalations than prescribed. If you are unsure about anything, ask your doctor, pharmacist, or nurse for clarification.
Adults (Including Elderly)
Maintenance Therapy for COPD and Chronic Asthma
Usual dose: 1–2 puffs (20–40 micrograms) inhaled four times daily
Maximum dose: 12 puffs (240 micrograms) per day
The dose should be spread evenly throughout the day, typically at approximately 6-hour intervals, to maintain consistent bronchodilation. Your doctor will determine the optimal number of puffs per dose based on the severity of your condition and your response to treatment.
Children and Adolescents
Ipravent pressurised inhalation solution is not intended for use in children and adolescents. This formulation is approved for adults only. Alternative ipratropium bromide formulations, such as nebuliser solutions at adjusted doses, may be available for paediatric use under specialist supervision. Consult a paediatrician or paediatric respiratory specialist for guidance.
How to Use the Inhaler
It is essential to use the inhaler correctly to ensure the medicine reaches your lungs effectively. Breathe in as slowly as possible just before and during actuation. Follow these steps carefully:
Before using the inhaler for the first time, or if you have not used it for three days or more, you must prime it. Remove the mouthpiece cap, point the mouthpiece away from you, and press the canister twice (one press at a time) to spray two doses into the air. This ensures the valve mechanism is working properly and the next dose will be accurately measured.
- Stand or sit upright. Remove the mouthpiece cap by pressing gently on both sides. Check the mouthpiece is clean and free from foreign objects inside and out.
- Hold the inhaler upright with your thumb on the bottom beneath the mouthpiece. Breathe out as long as is comfortable. Do not breathe in again yet.
- Place the mouthpiece between your teeth and close your lips around it. Do not bite.
- Breathe in through your mouth. Just as you begin to breathe in, press down on the top of the canister to release one dose. Continue breathing in steadily and deeply.
- Hold your breath for a few seconds, or as long as is comfortable, then remove the inhaler from your mouth.
- If your doctor has told you to take two puffs, wait about one minute before repeating steps 2–5.
- Replace the mouthpiece cap immediately after use to protect against dust. Press firmly until you hear a click.
Practise in front of a mirror the first few times. If you see mist escaping from the top of the inhaler or from the sides of your mouth, start the process again from step 2. People with weak hands may find it easier to hold the inhaler with both hands, placing both index fingers on the top and both thumbs beneath the mouthpiece.
Cleaning the Inhaler
Regular cleaning is important to ensure the inhaler functions properly. Remove the metal canister and cap, then wash the white mouthpiece with warm soapy water. Rinse with warm water and allow to dry naturally without using heat. Ensure the small hole in the mouthpiece has been rinsed through completely. Replace the canister and cap once dry. Do not place the metal canister in water.
Keeping Track of Doses
Each Ipravent canister provides 200 metered doses. However, there is no dose counter, and it is not possible to tell visually when the canister is empty – a small amount of liquid may remain. Replace your inhaler after 200 doses (typically after 3–4 weeks of regular use at the standard dose) to ensure you receive the correct amount of medicine with each puff.
Protecting Your Eyes
Take care not to get Ipravent spray in your eyes. If the spray accidentally enters your eyes, flush them immediately with running water. Symptoms of ocular exposure include eye pain, stinging, redness, dilated pupils, blurred vision, and seeing colours or halos around lights. Contact your doctor promptly if you experience any eye symptoms, as you may be developing acute narrow-angle glaucoma, which requires immediate medical treatment.
Missed Dose
If you forget a dose, take it as soon as you remember. However, if it is nearly time for your next dose, skip the missed dose entirely. Do not take a double dose to make up for a forgotten one.
Overdose
If you take too many puffs or if a child accidentally uses the inhaler, contact your doctor, hospital, or poison control centre immediately. Bring the inhaler and any other medicines you use (in their packaging if possible). Symptoms of overdose may include dry mouth, rapid heartbeat (tachycardia), dilated pupils, difficulty urinating, headache, constipation, and dizziness.
Stopping Ipravent
Use Ipravent for the duration prescribed by your doctor. Do not stop using it without consulting your doctor first, even if you feel better. Stopping maintenance bronchodilator therapy abruptly can lead to worsening of respiratory symptoms. If you have further questions about this medicine, talk to your doctor or pharmacist.
What Are the Side Effects of Ipravent?
The most common side effects of Ipravent include headache, dizziness, dry mouth, nausea, stomach discomfort, cough, and throat irritation. In rare cases, it can cause paradoxical bronchospasm (worsening wheezing), allergic reactions, or ocular complications.
Like all medicines, Ipravent can cause side effects, although not everybody gets them. Most side effects are mild and transient. If any side effect becomes severe or persistent, or if you notice any effect not listed below, contact your doctor or pharmacist.
- Wheezing or breathing difficulties after using Ipravent (paradoxical bronchospasm) – do not take another dose unless your doctor has specifically instructed you to
- Swelling of the mouth, face, sudden breathing difficulties, drop in blood pressure, or throat tightness – these may be signs of an allergic reaction or angioedema
- Eye problems after accidental ocular exposure – you may be developing narrow-angle glaucoma, which needs immediate treatment
Common
May affect up to 1 in 10 people
- Headache, dizziness
- Dry mouth, nausea, stomach discomfort or pain
- Disturbed bowel function
- Cough and throat irritation immediately after inhalation
Uncommon
May affect up to 1 in 100 people
- Itching, skin rash
- Unexpected chest tightness, throat swelling, dry throat
- Diarrhoea, constipation, or vomiting
- Mouth ulcers or lip sores
- Difficulty urinating, particularly in patients with pre-existing bladder emptying problems
Rare
May affect up to 1 in 1,000 people
- Difficulty focusing vision at different distances (accommodation disorder)
- Increased heart rate (tachycardia)
- Atrial fibrillation (irregular heart rhythm)
- Urticaria (hives)
Frequency Not Known
Reported but exact frequency cannot be estimated
- Taste changes
- Shortness of breath
- Nasal congestion
- Dry nasal membranes
If you notice any side effects not listed here, or if any side effect becomes troublesome, contact your doctor or pharmacist. Reporting suspected side effects helps healthcare authorities continuously monitor the benefit-risk balance of medicines.
How Should You Store Ipravent?
Store Ipravent out of reach of children, away from direct sunlight, heat, and frost. Do not expose the pressurised canister to temperatures above 50°C. Do not use after the expiry date printed on the packaging.
Keep the inhaler out of the sight and reach of children at all times. Check the expiry date on the carton and canister label before each use. The expiry date refers to the last day of the stated month. Do not use Ipravent after this date.
Protect the inhaler from direct sunlight, heat, and frost. If the inhaler has been exposed to cold temperatures, remove the metal canister from the plastic housing and warm it between your hands for at least two minutes before use. The canister contains a pressurised liquid – do not expose it to temperatures above 50°C. Do not attempt to open, puncture, or incinerate the canister, even if it appears to be empty.
Do not dispose of medicines via wastewater or household waste. Return any unused or expired inhalers to your pharmacy for safe disposal. This helps protect the environment from pharmaceutical contamination.
Each Ipravent inhaler contains 12.3 g of the propellant norfluran (HFA 134a), a hydrofluorocarbon. This corresponds to approximately 0.018 tonnes of CO2 equivalent (global warming potential GWP = 1,430). Dry powder inhalers (DPIs), where available as alternatives, generally have a lower carbon footprint. Discuss options with your doctor if environmental impact is a concern, but never switch inhalers without medical guidance.
What Does Ipravent Contain?
Each Ipravent spray dose delivers 20 micrograms of ipratropium bromide (as monohydrate). The inhaler also contains the propellant norfluran (HFA 134a), anhydrous citric acid, anhydrous ethanol, and purified water.
Active Ingredient
The active substance is ipratropium bromide. Each metered spray dose delivers 20 micrograms of ipratropium bromide (as monohydrate). Each canister contains a total of 200 metered doses.
Inactive Ingredients (Excipients)
The other ingredients are:
- Norfluran (HFA 134a) – the propellant that creates the aerosol spray; this is a non-CFC propellant
- Anhydrous citric acid – a stabiliser that maintains the pH of the solution
- Anhydrous ethanol – a co-solvent (8.4 mg per dose; does not produce noticeable effects)
- Purified water – used as a solvent in the formulation
Inhaler Description and Packaging
Ipravent is a colourless solution contained in a 19 ml silver anodised aluminium canister fitted with a metered-dose valve (50 microlitres per actuation) and a polypropylene plastic actuator with mouthpiece cap. The mouthpiece assembly includes a thermoplastic centre piece, dosing chamber, elastomer seals and packing, a metal ring, and a spring. Each package contains one canister providing 200 metered doses.
How Does Ipravent Work in the Body?
Ipravent works by blocking muscarinic M3 receptors in bronchial smooth muscle, preventing acetylcholine from causing airway constriction. This results in bronchodilation – relaxation and widening of the airways – making it easier to breathe. Onset of action is approximately 15 minutes, with peak effect at 1–2 hours.
The airways are lined with smooth muscle that is controlled by the autonomic nervous system. The parasympathetic branch of this system releases the neurotransmitter acetylcholine, which binds to muscarinic receptors (primarily the M3 subtype) on bronchial smooth muscle cells. This binding triggers a cascade of intracellular events that leads to smooth muscle contraction, narrowing the airways and increasing resistance to airflow. In patients with COPD and asthma, this cholinergic tone is often elevated, contributing to chronic bronchoconstriction.
Ipratropium bromide is a quaternary ammonium compound that competitively antagonises acetylcholine at muscarinic M3 receptors. Because it is a quaternary amine, it carries a permanent positive charge, which means it is poorly absorbed across biological membranes. This characteristic is clinically important because it ensures that ipratropium acts primarily at the site of delivery – the airways – with minimal systemic absorption and therefore fewer systemic anticholinergic side effects compared to atropine.
In addition to directly relaxing bronchial smooth muscle, ipratropium bromide reduces mucus secretion from bronchial glands to a modest degree, although it does not change the viscosity or composition of mucus. This can provide a small additional benefit in conditions like chronic bronchitis where excess mucus production contributes to airway obstruction.
Pharmacokinetic Profile
Following inhalation, ipratropium bromide is deposited in the lungs where it exerts its local bronchodilatory effect. The onset of action is typically within 15 minutes of inhalation, with the peak bronchodilatory effect occurring at approximately 1–2 hours. The duration of action is 4–6 hours, which necessitates dosing four times daily for sustained bronchodilation throughout the day.
Only a small fraction of the inhaled dose reaches the systemic circulation. The majority of the drug that is swallowed during inhalation passes through the gastrointestinal tract, where absorption is very poor (less than 2% bioavailability after oral administration). The small amount that is absorbed systemically is rapidly eliminated, with a terminal elimination half-life of approximately 1.6 hours. Ipratropium is metabolised to inactive metabolites and excreted primarily via the kidneys.
The low systemic bioavailability of inhaled ipratropium is a significant advantage, as it means the drug can provide effective local bronchodilation in the lungs while minimising the risk of systemic anticholinergic effects such as tachycardia, urinary retention, and central nervous system effects that are more commonly seen with non-selective anticholinergic agents like atropine.
Frequently Asked Questions About Ipravent
Ipravent is used to make breathing easier in adults with chronic obstructive pulmonary disease (COPD) and chronic asthma. It contains ipratropium bromide, an anticholinergic bronchodilator that works by blocking muscarinic receptors in the airways, causing the bronchial muscles to relax and the airways to open. It is used as maintenance therapy and is not intended as a rescue inhaler for acute breathlessness.
Prime the inhaler by spraying twice into the air before first use or if not used for 3+ days. Stand or sit upright, exhale fully, place the mouthpiece between your teeth and close your lips around it. As you start to breathe in slowly, press the canister to release one dose. Continue inhaling deeply, then hold your breath for a few seconds. Wait about one minute between puffs. Replace the cap after use. Practise in front of a mirror and use a spacer if coordination is difficult.
The most common side effects include headache, dizziness, dry mouth, nausea, stomach discomfort, disturbed bowel function, cough, and throat irritation right after inhaling. Dry mouth is particularly notable with long-term use and may contribute to dental problems, so brushing teeth with fluoride toothpaste twice daily is recommended. Most side effects are mild and improve over time.
No, the Ipravent pressurised inhalation spray is not intended for children or adolescents. This formulation is approved for adults only, including elderly patients. Alternative ipratropium bromide formulations such as nebuliser solutions may be suitable for children under specialist medical supervision. Always consult a paediatrician or respiratory specialist for guidance on appropriate treatments for children.
If Ipravent spray accidentally gets into your eyes, flush them immediately with running water. You may experience eye pain, stinging, redness, dilated pupils, blurred vision, and visual disturbances such as seeing colours or halos. Contact your doctor promptly, as there is a risk of developing narrow-angle glaucoma, a serious condition that requires immediate medical treatment to prevent permanent vision loss.
Yes, Ipravent is commonly used alongside other inhaled bronchodilators, particularly short-acting beta-2 agonists like salbutamol and xanthine derivatives like theophylline. The combination can provide enhanced bronchodilation because the drugs work through different mechanisms. However, avoid combining Ipravent with other inhaled anticholinergics (like tiotropium) without medical advice. Ipravent can also be used with a spacer device such as Aerochamber Plus for patients who have difficulty coordinating inhalation and actuation.
References
This article is based on the following international medical guidelines and peer-reviewed sources. All medical claims have evidence level 1A, the highest quality of evidence based on systematic reviews of randomised controlled trials.
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease – 2024 Report. GOLD; 2024.
- Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention – 2024 Update. GINA; 2024.
- Gross NJ, Skorodin MS. Role of the parasympathetic system in airway obstruction due to emphysema. New England Journal of Medicine. 1984;311(7):421–425.
- Rodrigo GJ, Castro-Rodriguez JA. Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis. Thorax. 2005;60(9):740–746.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd list. Geneva: WHO; 2023.
- European Medicines Agency (EMA). Ipratropium bromide – Summary of Product Characteristics. EMA product information database. Accessed January 2026.
- National Institute for Health and Care Excellence (NICE). Chronic obstructive pulmonary disease in over 16s: diagnosis and management. NICE guideline [NG115]. Updated 2023.
- British National Formulary (BNF). Ipratropium bromide. NICE BNF monograph. Accessed January 2026.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, a group of licensed specialist physicians with expertise in pulmonology, clinical pharmacology, and respiratory medicine.
Medical Writers
Board-certified physicians specialising in respiratory medicine and clinical pharmacology with documented academic and clinical experience.
Medical Reviewers
Independent review board ensuring clinical accuracy, adherence to international guidelines (GOLD, GINA, NICE, WHO), and evidence level 1A standards.
All content follows the GRADE evidence framework and is reviewed against current international guidelines. We have no commercial funding or pharmaceutical sponsorship. For more information, see our editorial standards and medical team pages.